Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tegretol Prolonged Release 200mg tablets
0408010C0BBAEAG
|
Tegretol | Carbamazepine | Central Nervous System | 72,564 |
|
Tegretol Prolonged Release 400mg tablets
0408010C0BBAFAH
|
Tegretol | Carbamazepine | Central Nervous System | 70,207 |
|
Carbamazepine 100mg tablets
0408010C0AAABAB
|
Carbamazepine | Carbamazepine | Central Nervous System | 59,777 |
|
Carbamazepine 200mg tablets
0408010C0AAACAC
|
Carbamazepine | Carbamazepine | Central Nervous System | 57,672 |
|
Tegretol 200mg tablets
0408010C0BBABAC
|
Tegretol | Carbamazepine | Central Nervous System | 50,486 |
|
Tegretol 100mg tablets
0408010C0BBAAAB
|
Tegretol | Carbamazepine | Central Nervous System | 40,763 |
|
Tegretol 400mg tablets
0408010C0BBACAD
|
Tegretol | Carbamazepine | Central Nervous System | 24,463 |
|
Carbamazepine 400mg tablets
0408010C0AAADAD
|
Carbamazepine | Carbamazepine | Central Nervous System | 24,446 |
|
Carbamazepine 200mg modified-release tablets
0408010C0AAAGAG
|
Carbamazepine | Carbamazepine | Central Nervous System | 20,039 |
|
Carbamazepine 400mg modified-release tablets
0408010C0AAAHAH
|
Carbamazepine | Carbamazepine | Central Nervous System | 14,817 |
|
Carbamazepine 100mg/5ml oral suspension sugar free
0408010C0AAAPAP
|
Carbamazepine | Carbamazepine | Central Nervous System | 14,380 |
|
Tegretol 100mg/5ml liquid (Novartis)
0408010C0BBADAP
|
Tegretol | Carbamazepine | Central Nervous System | 11,924 |
|
Carbamazepine 250mg suppositories
0408010C0AAAVAV
|
Carbamazepine | Carbamazepine | Central Nervous System | 76 |
|
Carbamazepine 500mg/5ml oral suspension
0408010C0AAAYAY
|
Carbamazepine | Carbamazepine | Central Nervous System | 28 |
|
Carbamazepine 125mg suppositories
0408010C0AAAUAU
|
Carbamazepine | Carbamazepine | Central Nervous System | 22 |
|
Carbagen 200mg tablets
0408010C0BFADAC
|
Carbagen | Carbamazepine | Central Nervous System | 20 |
|
Carbamazepine 100mg/5ml oral liquid
0408010C0AABDBD
|
Carbamazepine | Carbamazepine | Central Nervous System | 14 |
|
Carbagen SR 400mg tablets
0408010C0BFABAH
|
Carbagen | Carbamazepine | Central Nervous System | 7 |
|
Carbagen SR 200mg tablets
0408010C0BFAAAG
|
Carbagen | Carbamazepine | Central Nervous System | 5 |
|
Carbamazepine 200mg/5ml oral liquid
0408010C0AAAXAX
|
Carbamazepine | Carbamazepine | Central Nervous System | 5 |
|
Carbagen 400mg tablets
0408010C0BFAEAD
|
Carbagen | Carbamazepine | Central Nervous System | 2 |
|
Carbamazepine 100mg chewable tablets sugar free
0408010C0AAAJAJ
|
Carbamazepine | Carbamazepine | Central Nervous System | 2 |
|
Curatil Prolonged Release 200mg tablets
0408010C0BHAAAG
|
Curatil | Carbamazepine | Central Nervous System | 2 |
|
Carbagen 100mg tablets
0408010C0BFACAB
|
Carbagen | Carbamazepine | Central Nervous System | 1 |
|
Carbamazepine 120mg/5ml oral liquid
0408010C0AABFBF
|
Carbamazepine | Carbamazepine | Central Nervous System | 1 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.